Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report.
Gastric cancer
Immune-related adverse events
Nivolumab
Tumor response
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
19 Oct 2020
19 Oct 2020
Historique:
received:
07
09
2020
accepted:
15
10
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy. Recent clinical trials have established the clinical utility of nivolumab in the third-line treatment of such patients. Immune-related adverse events (irAE) have been focused as a promising predictor for tumor response to nivolumab. This report aims to present a long-term survivor of recurrent gastric cancer who was followed up without any treatments after the nivolumab discontinuation because of irAE. A 65-year-old male with stage III gastric cancer (cT4aN1M0) underwent surgery after neoadjuvant chemotherapy. Owing to the final pathological stage IIIB (ypT4bN1M0), the patient received adjuvant chemotherapy. Nevertheless, during adjuvant chemotherapy 1-year post-surgery, computed tomography (CT) revealed lymph node swelling in station no. 9. Thus, upon diagnosis with lymph node recurrence, the patient was treated with two courses of capecitabine + oxaliplatin and three courses of ramucirumab + paclitaxel as the first- and second-line regimens, respectively. Based on these regimens, the patient had a progressive disease to chemotherapy. Consequently, we administered nivolumab as the third-line regimen. After four courses of nivolumab, CT revealed a significant shrinkage of the metastatic lymph node, with a 45.6% reduction. We confirmed a partial response during 11 courses of nivolumab. Since the occurrence of grade 4 diabetes mellitus after 12 courses of nivolumab, the patient was followed up without any treatment after the nivolumab discontinuation. Currently, the patient remains a partial response for 15 months, since the nivolumab discontinuation and is alive for 31 months after disease recurrence. Acute irAE during nivolumab chemotherapy could be one of the crucial clinical factors to predict tumor suppression in patients with advanced gastric cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy. Recent clinical trials have established the clinical utility of nivolumab in the third-line treatment of such patients. Immune-related adverse events (irAE) have been focused as a promising predictor for tumor response to nivolumab. This report aims to present a long-term survivor of recurrent gastric cancer who was followed up without any treatments after the nivolumab discontinuation because of irAE.
CASE PRESENTATION
METHODS
A 65-year-old male with stage III gastric cancer (cT4aN1M0) underwent surgery after neoadjuvant chemotherapy. Owing to the final pathological stage IIIB (ypT4bN1M0), the patient received adjuvant chemotherapy. Nevertheless, during adjuvant chemotherapy 1-year post-surgery, computed tomography (CT) revealed lymph node swelling in station no. 9. Thus, upon diagnosis with lymph node recurrence, the patient was treated with two courses of capecitabine + oxaliplatin and three courses of ramucirumab + paclitaxel as the first- and second-line regimens, respectively. Based on these regimens, the patient had a progressive disease to chemotherapy. Consequently, we administered nivolumab as the third-line regimen. After four courses of nivolumab, CT revealed a significant shrinkage of the metastatic lymph node, with a 45.6% reduction. We confirmed a partial response during 11 courses of nivolumab. Since the occurrence of grade 4 diabetes mellitus after 12 courses of nivolumab, the patient was followed up without any treatment after the nivolumab discontinuation. Currently, the patient remains a partial response for 15 months, since the nivolumab discontinuation and is alive for 31 months after disease recurrence.
CONCLUSIONS
CONCLUSIONS
Acute irAE during nivolumab chemotherapy could be one of the crucial clinical factors to predict tumor suppression in patients with advanced gastric cancer.
Identifiants
pubmed: 33074364
doi: 10.1186/s40792-020-01050-1
pii: 10.1186/s40792-020-01050-1
pmc: PMC7572942
doi:
Types de publication
Journal Article
Langues
eng
Pagination
271Références
Gastric Cancer. 2020 Feb 14;:
pubmed: 32060757
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Gastroenterol Surg. 2020 Jan 30;4(1):21-29
pubmed: 32021955
J Clin Oncol. 2018 Jul 1;36(19):1922-1929
pubmed: 29746229
BMC Cancer. 2019 Oct 21;19(1):974
pubmed: 31638948
Curr Oncol Rep. 2020 Mar 21;22(4):39
pubmed: 32200442
Gastric Cancer. 2020 May;23(3):510-519
pubmed: 31863227
J Surg Oncol. 2018 Jul;118(1):77-85
pubmed: 29878357
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282824
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Immunother Cancer. 2018 Oct 11;6(1):106
pubmed: 30314524
Gastric Cancer. 2019 Mar;22(2):344-354
pubmed: 30506519
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Int J Mol Sci. 2020 Jan 10;21(2):
pubmed: 31936762
Cancer Chemother Pharmacol. 2020 Feb;85(2):265-272
pubmed: 31907646
Ann Oncol. 2019 Mar 1;30(3):424-430
pubmed: 30624548
J Immunother Cancer. 2019 Jan 31;7(1):24
pubmed: 30704511